Isolagen Inc., of Houston, appointed Kimberley Forbes-McKean senior vice president and chief technical science officer.
MDS Pharma Services, of Montreal, hired Robert Challender as vice president for finance of late-stage development.
Memory Pharmaceuticals Corp., of Montvale, N.J., appointed David Lowe chief scientific officer.
Merial Ltd., of Duluth, Ga., appointed Gerald Belle executive chairman.
Nautilus Biotech, of Paris, appointed Silvano Fumero chairman and William Respess to its board.
NitroMed Inc., of Lexington, Mass., appointed Lawrence Bloch chief financial officer and chief business officer.
Nuvelo Inc., of Sunnyvale, Calif., appointed Burton Sobel to its board.
Osmotics Corp., of Denver, appointed Peter Elias chief scientific officer.
Parexel International Corp., of Boston, appointed Antoni Piergies vice president, clinical pharmacology and director of the clinical pharmacology research unit at the Harbor Hospital Center in Baltimore, Md.
Sonus Pharmaceuticals Inc., of Bothell, Wash., appointed Alan Fuhrman senior vice president and chief financial officer.
The Science Center, of Philadelphia, appointed Pradip Banerjee CEO.
Transave Inc., of Monmouth Junction, N.J., appointed Andrew Gorman vice president of business development.
Vela Pharmaceuticals Inc., of Ewing, N.J., elected Praveen Tyle to its scientific advisory board.
Ventiv Pharma Services, of Somerset, N.J., appointed Jack Rubin chief compliance officer.
Vicuron Pharmaceuticals Inc., of King of Prussia, Pa., appointed Cheryl Wenzinger to its board.
VizX Labs, of Seattle, appointed William Barna director of sales.